whitepaper
Whitepaper: Standard versus “hybrid” FIH trial advantages and challenges
This whitepaper examines key considerations to take into account when deciding whether to run a standard FIH in HVs or a hybrid FIH clinical trial.
List view / Grid view
R&D
news
Lilly to create $700mn Institute for Genetic Medicine
Investing $700mn to establish a new site, Eli Lilly plans to fuel the development of genetic medicines through the company’s new Institute for Genetic Medicine.
news
β-thalassemia patients achieve transfusion independence with gene therapy
Over 90 percent of β-thalassemia patients treated with Betibeglogene autotemcel (beti-cel) achieved transfusion independence lasting over a year.
article
EU pharmaceutical regulatory outlook for 2022
How will a new regulatory landscape impact the EU and UK pharma industries? Early 2022 will see major new clinical trial legislation come into effect, with proposals for an entirely new regulatory regime promised by the end of the year. Paul Ranson, Consultant at Morgan Lewis, reflects on this and…
article
Prioritising bold innovation throughout the pandemic and beyond
Following his first full year as Managing Director UK, Ireland & Nordics for Novartis Pharmaceuticals, healthcare leader Chinmay Bhatt shares his learnings from the pandemic and reflects on what’s next.
whitepaper
Blog: Types of pure water: what you need to know
Making the decision on which type of pure water you need for your application can be difficult. This blog provides a quick guide to pure water types.
podcasts
EPR Podcast Episode 9 – Future of ATMPs – Jérôme Larghero and Julien Textoris, bioMérieux
Is the future of cell and gene therapy autologous or allogeneic? Which solid tumour may receive the first cell therapy treatment? How will the use of ATMPs in cancer care change our healthcare structures in years to come? Discover all this and more in this podcast with bioMérieux.
video
Video: ELGA Veolia brand corporate video 2020
At ELGA we are dedicated to providing water system solutions that empower scientists and researchers worldwide to do what they do best, uninterrupted.
article
European Pharmaceutical Review Issue 1 2022
In our latest journal, discover the innovations enabling drugs to be delivered across the blood-brain barrier, the challenges associated with downstream purification of cell and gene therapies, as well as applications of NIR spectroscopy in ingredient analysis. Also featured in this issue, explore the development and future potential of radiomolecular…
news
FDA aims to advance non-addictive opioid alternatives for acute pain management
The U.S. Food and Drug Administration (FDA) has taken new steps aimed at fostering the development of non-addictive alternatives to opioids to manage acute pain and decreasing exposure to opioids and preventing new addiction.
article
2021 bio/pharma financial round-up
European Pharmaceutical Review investigates the financial results of some of the top 10 pharma and biopharma companies worldwide.
news
Nexviazyme® improves respiration and mobility long-term in Pompe disease patients
Two-year data shows Pompe disease patients treated with Nexviazyme® (avalglucosidase alfa) have sustained improvements in respiratory function and mobility.
whitepaper
Whitepaper: Analysing water purity for advanced chromatographic applications
Download this whitepaper to find out how the purity of bottled water compares to the purity of water produced by an ELGA water purification system.
article
Phase I oncology studies: rule- versus model-based design
In this article, Karen Ooms, Head of Statistics at Quanticate, compares the rule- and model-based approaches to Phase I trial design, exploring their benefits and weaknesses in defining maximum tolerated dose for oncology products.
article
The microbiome: unlocking the Fourth Industrial (Bio) Revolution
The impending ‘Bio Revolution’, with the microbiome at its foundation, offers ground-breaking solutions and a wealth of opportunity in data science and bioinformatics, explains Anthony Finbow of Eagle Genomics.
